282 related articles for article (PubMed ID: 12234977)
1. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J
Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
3. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice.
Yim JH; Wu SJ; Casey MJ; Norton JA; Doherty GM
J Immunol; 1997 Feb; 158(3):1284-92. PubMed ID: 9013971
[TBL] [Abstract][Full Text] [Related]
4. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
5. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines.
Akiyama Y; Watanabe M; Maruyama K; Ruscetti FW; Wiltrout RH; Yamaguchi K
Gene Ther; 2000 Dec; 7(24):2113-21. PubMed ID: 11223993
[TBL] [Abstract][Full Text] [Related]
7. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
9. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
10. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
12. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effect on melanoma by in vivo direct injection of packaging cells transfected recombinant IL-2 gene].
Zhu Y; Wu Y; Hui Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):154-8. PubMed ID: 10453513
[TBL] [Abstract][Full Text] [Related]
14. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
Ledda MF; Adris S; Bravo AI; Bover L; Carbone C; Paleolog E; Mordoh J; Chernajovsky Y; Podhajcer OL
Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):769-78. PubMed ID: 8832108
[TBL] [Abstract][Full Text] [Related]
15. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells.
Sun WH; Kreisle RA; Phillips AW; Ershler WB
Cancer Res; 1992 Oct; 52(19):5412-5. PubMed ID: 1394147
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of B16 melanoma growth in vivo by retroviral vector-mediated human ribonuclease inhibitor.
Wang T; Yang M; Chen J; Watkins T; Xiuyun C
Angiogenesis; 2005; 8(1):73-81. PubMed ID: 16132620
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo.
Niu G; Heller R; Catlett-Falcone R; Coppola D; Jaroszeski M; Dalton W; Jove R; Yu H
Cancer Res; 1999 Oct; 59(20):5059-63. PubMed ID: 10537273
[TBL] [Abstract][Full Text] [Related]
18. Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation.
Zhang J; Wang Q; Zhao D; Cao X
Cytotherapy; 2007; 9(4):386-96. PubMed ID: 17573614
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo targeting of gene expression to melanoma cells.
Vile RG; Hart IR
Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
[TBL] [Abstract][Full Text] [Related]
20. Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma.
Yim JH; Wu SJ; Lowney JK; Vander Velde TL; Doherty GM
J Interferon Cytokine Res; 1999 Jul; 19(7):723-9. PubMed ID: 10454342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
